Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK2 | O75116 | 4/20 | 0.36 |
| ▸ | ROCK1 | Q13464 | 4/20 | 0.36 |
| ▸ | CDC42BPB | Q9Y5S2 | 4/20 | 0.36 |
| ▸ | MET | P08581 | 1/20 | 0.34 |
| ▸ | CDC42BPA | Q5VT25 | 2/20 | 0.33 |
| ▸ | CSF1R | P07333 | 2/20 | 0.33 |
| ▸ | KIT | P10721 | 2/20 | 0.33 |
| ▸ | LRRK2 | Q5S007 | 3/20 | 0.32 |
| ▸ | GABRP | O00591 | 1/20 | 0.32 |
| ▸ | GABRD | O14764 | 1/20 | 0.32 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.32 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.32 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.32 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.32 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.32 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.32 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.32 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.32 |
| ▸ | GABRA4 | P48169 | 1/20 | 0.32 |
| ▸ | GABRE | P78334 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1887133 | 0.77 | CYP3A4 (0.58) | CSF1RKITLRRK2CYP3A4CYP2C19 | |
| SCHEMBL27890843 | 0.77 | LRRK2 (0.47) | ROCK2ROCK1CDC42BPBMETCDC42BPA | |
| SCHEMBL1891277 | 0.75 | CYP2C19 (0.47) | CSF1RKITCYP3A4CYP2C19 | |
| SCHEMBL1893214 | 0.75 | CSF1R (0.60) | CSF1RKITCYP3A4CYP2C19 | |
| SCHEMBL1885797 | 0.74 | CYP3A4 (0.46) | CSF1RKITCYP3A4CYP2C19 | |
| SCHEMBL15456715 | 0.74 | CYP2C19 (0.41) | CSF1RKITCYP3A4CYP2C19 | |
| SCHEMBL15456473 | 0.74 | CYP3A4 (0.40) | CSF1RKITCYP3A4CYP2C19 | |
| SCHEMBL1882322 | 0.74 | CYP3A4 (0.63) | CSF1RKITCYP3A4CYP2C19 | |
| SCHEMBL30695631 | 0.74 | CYP3A4 (0.63) | CSF1RKITCYP3A4CYP2C19 | |
| SCHEMBL1893091 | 0.73 | CYP3A4 (0.49) | METCSF1RKITCYP3A4CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9096593-B2 | Compounds and methods for kinase modulation, and indications therefor | PLEXXIKON INC. (US) | 2015-08-04 | — | — | US | disclosed |
| US-9096593-B2 | Compounds and methods for kinase modulation, and indications therefor | PLEXXIKON INC. (US) | 2015-08-04 | — | — | US | disclosed |
| US-9096593-B2 | Compounds and methods for kinase modulation, and indications therefor | PLEXXIKON INC. (US) | 2015-08-04 | — | — | US | disclosed |
| US-20140045840-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON INC. (US) | 2014-02-13 | — | — | US | disclosed |
| US-20140045840-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON INC. (US) | 2014-02-13 | — | — | US | disclosed |
| US-20140045840-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON INC. (US) | 2014-02-13 | — | — | US | disclosed |
| EP-2496086-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | Plexxikon, Inc. (US) | 2012-09-12 | — | — | EP | disclosed |
| WO-2011057022-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON, INC. (US) | 2011-05-12 | — | — | WO | disclosed |
| WO-2011057022-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON, INC. (US) | 2011-05-12 | — | — | WO | disclosed |
| US-20110112127-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON, INC. | 2011-05-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110112127-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | KIT, FLT3, BRAF | ROCK2 1092/4885ROCK1 680/4885CDC42BPB 922/4885 |
| US-20140045840-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | KIT, FLT3, BRAF | ROCK2 1092/4885ROCK1 680/4885CDC42BPB 922/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.